Nebulized Tyvaso — Cost of Sales
United Therapeutics Nebulized Tyvaso — Cost of Sales increased by 34.4% to $8.60M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1.2%, from $8.50M to $8.60M. Over 3 years (FY 2021 to FY 2025), Nebulized Tyvaso — Cost of Sales shows relatively stable performance with a 0.5% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
A decrease relative to revenue suggests improved manufacturing efficiencies or economies of scale, while an increase may signal rising production or supply chain costs.
Detailed definition
This metric captures the direct costs associated with manufacturing, packaging, and distributing the nebulized drug prod...
Peer comparison
Comparable to cost of goods sold (COGS) for specific pharmaceutical product lines at peer biotech firms.
uthr_segment_nebulized_tyvaso_cost_of_salesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $6.70M | $6.70M | $6.70M | $6.70M | $6.20M | $7.40M | $9.80M | $9.00M | $8.90M | $8.40M | $9.40M | $7.40M | $8.50M | $5.60M | $6.70M | $6.40M | $8.60M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -7.5% | +19.4% | +32.4% | -8.2% | -1.1% | -5.6% | +11.9% | -21.3% | +14.9% | -34.1% | +19.6% | -4.5% | +34.4% |
| YoY Change | — | — | — | +0.0% | — | — | +46.3% | — | +43.5% | +13.5% | -4.1% | -17.8% | -4.5% | -33.3% | -28.7% | -13.5% | +1.2% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is United Therapeutics's nebulized tyvaso — cost of sales?
- United Therapeutics (UTHR) reported nebulized tyvaso — cost of sales of $8.60M in Q1 2026.
- How has United Therapeutics's nebulized tyvaso — cost of sales changed year-over-year?
- United Therapeutics's nebulized tyvaso — cost of sales increased by 1.2% year-over-year, from $8.50M to $8.60M.
- What is the long-term trend for United Therapeutics's nebulized tyvaso — cost of sales?
- Over 3 years (2021 to 2025), United Therapeutics's nebulized tyvaso — cost of sales has grown at a 0.5% compound annual growth rate (CAGR), from $26.80M to $27.20M.
- What does nebulized tyvaso — cost of sales mean?
- The direct costs incurred to manufacture and supply the nebulized version of the company's pulmonary hypertension drug.